Podcast to Discuss Therapy Management for Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Axitinib Plus an Immune Checkpoint Inhibitor (May, 10.1007/s12325-023-02513-1, 2023)

被引：0
|
作者：
Ornstein, Moshe C. [1 ]
Wood, Laura S. [2 ]
机构：
[1] Cleveland Clin, Hematol & Med Oncol, Cleveland, OH 44195 USA
[2] Cleveland Clin, Cleveland, OH USA
来源：
ADVANCES IN THERAPY | 2023年 / 40卷 / 09期
关键词：
Adverse event; Axitinib; Combination; First-line; Immune checkpoint inhibitor; Renal cell carcinoma; Therapy management;
D O I：
10.1007/s12325-023-02593-z
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
引用
收藏
页码：4116 / 4116
页数：1
相关论文
共 50 条
  • [21] Targeted Therapies Following First-Line Immune Checkpoint Inhibitor Combination in Metastatic Renal Cell Carcinoma: A Single Center Experience
    Dizman, Nazli
    Bergerot, Paulo G.
    Bergerot, Cristiane D.
    Hsu, JoAnn
    Pal, Sumanta K.
    KIDNEY CANCER, 2019, 3 (03) : 171 - 176
  • [22] EFFECTS OF FIRST-LINE IMMUNE CHECKPOINT INHIBITORS IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA NOT MEETING TRIAL ELIGIBILITY CRITERIA
    Nemoto, Yuki
    Ishihara, Hiroki
    Nakamura, Kazutaka
    Tachibana, Hidekazu
    Fukuda, Hironori
    Yoshida, Kazuhiko
    Kobayashi, Hirohito
    Iizuka, Junpei
    Shimmura, Hiroaki
    Hashimoto, Yasunobu
    Tanabe, Kazunari
    Kondo, Tsunenori
    Takagi, Toshio
    JOURNAL OF UROLOGY, 2022, 207 (05): : E173 - E173
  • [23] Durability of Response with First-Line Combined Immune Checkpoint Inhibitor Therapy Compared to Checkpoint Inhibitor with VEGFR-TKI in Advanced Clear Cell Renal Cell Carcinoma
    Zaemes, Jacob
    McDermott, David F.
    Regan, Meredith M.
    Atkins, Michael B.
    KIDNEY CANCER, 2024, 8 (01) : 93 - 97
  • [24] Impact of smoking status on clinical outcomes in patients with metastatic renal cell carcinoma treated with first-line immune checkpoint inhibitor-based regimens
    Saad, Eddy
    Gebrael, Georges
    Semaan, Karl
    Eid, Marc
    Saliby, Renee Maria
    Labaki, Chris
    Sayegh, Nicolas
    Wells, J. Connor
    Takemura, Kosuke
    Ernst, Matthew Scott
    Lemelin, Audreylie
    Basappa, Naveen S.
    Wood, Lori A.
    Powles, Thomas
    Ernst, D. Scott
    Lalani, Aly-Khan A.
    Agarwal, Neeraj
    Xie, Wanling
    Heng, Daniel Y. C.
    Choueiri, Toni K.
    ONCOLOGIST, 2024, 29 (08): : 699 - 706
  • [25] Prognostic outcomes in patients with metastatic renal cell carcinoma receiving second-line treatment with tyrosine kinase inhibitor following first-line immune-oncology combination therapy
    Matsushita, Yuto
    Kojima, Takahiro
    Osawa, Takahiro
    Sazuka, Tomokazu
    Hatakeyama, Shingo
    Goto, Keisuke
    Numakura, Kazuyuki
    Yamana, Kazutoshi
    Kandori, Shuya
    Fujita, Kazutoshi
    Ueda, Kosuke
    Tanaka, Hajime
    Tomida, Ryotaro
    Kurahashi, Toshifumi
    Bando, Yukari
    Nishiyama, Naotaka
    Kimura, Takahiro
    Yamashita, Shimpei
    Kitamura, Hiroshi
    Miyake, Hideaki
    INTERNATIONAL JOURNAL OF UROLOGY, 2024, 31 (05) : 526 - 533
  • [26] First-line Immune Checkpoint Inhibitor Combinations in Metastatic Renal Cell Carcinoma: Where Are We Going, Where Have We Been?
    Adashek, Jacob J.
    Breunig, Joshua J.
    Posadas, Edwin
    Bhowmick, Neil A.
    Ellis, Leigh
    Freedland, Stephen J.
    Kim, Hyung
    Figlin, Robert
    Gong, Jun
    DRUGS, 2022, 82 (04) : 439 - 453
  • [27] First-line Immune Checkpoint Inhibitor Combinations in Metastatic Renal Cell Carcinoma: Where Are We Going, Where Have We Been?
    Jacob J. Adashek
    Joshua J. Breunig
    Edwin Posadas
    Neil A. Bhowmick
    Leigh Ellis
    Stephen J. Freedland
    Hyung Kim
    Robert Figlin
    Jun Gong
    Drugs, 2022, 82 : 439 - 453
  • [28] Role of immune checkpoint inhibitor-based therapies for metastatic renal cell carcinoma in the first-line setting: A Bayesian network analysis
    Wang, Junpeng
    Li, Xin
    Wu, Xiaoqiang
    Wang, Zhiwei
    Zhang, Chan
    Cao, Guanghui
    Zhang, Xiaofan
    Peng, Feng
    Yan, Tianzhong
    EBIOMEDICINE, 2019, 47 : 78 - 88
  • [29] Effectiveness of Second-Line Cabozantinib in Metastatic Clear Cell Renal Cell Carcinoma Patients After First-Line Treatment with Immune Checkpoint Inhibitor-based Combinations
    Narang, Arshit
    Gebrael, Georges
    Jo, Yeonjung
    Thomas, Vinay Mathew
    Li, Haoran
    Fortuna, Gliceida Galarza
    Sayegh, Nicolas
    Tandar, Clara
    Tripathi, Nishita
    Chigarira, Beverly
    Srivastava, Ayana
    Chehade, Chadi Hage
    Nordblad, Blake
    Maughan, Benjamin L.
    Agarwal, Neeraj
    Swami, Umang
    KIDNEY CANCER, 2024, 8 (01) : 135 - 142
  • [30] Real-world outcomes of first-line tislelizumab plus axitinib in patients with metastatic non-clear cell renal cell carcinoma (mnccRCC)
    Huang, T.
    Jiang, L.
    Wei, W.
    Zheng, X.
    Zhang, Z.
    Guo, S.
    Han, H.
    Cai, X.
    Zhou, F.
    Dong, P.
    ANNALS OF ONCOLOGY, 2023, 34 : S1559 - S1560
12345